Bone Density and Cognitive Decline: Brain–Bone Link

What Do Your Bones Have to Do with Your Brain?

Bones may seem like an unlikely place to look for clues about cognitive health, yet growing research suggests that skeletal and brain health may be more closely connected than previously thought. Several observational studies have linked lower bone mineral density (BMD), osteoporosis and bone loss with a higher risk of cognitive impairment and dementia. A 2025 meta-analysis found evidence of a bidirectional relationship, with cognitive impairment associated with lower bone density and osteoporosis associated with greater cognitive impairment risk, although the authors noted that larger and more diverse longitudinal studies are needed to clarify the connection.

Researchers are investigating whether shared factors such as aging, chronic inflammation, physical inactivity, vascular health and hormonal changes help explain this association, while emerging research on the bone–brain axis suggests that bone may also communicate with the brain through the nervous system, blood vessels and signaling molecules such as osteocalcin and sclerostin. However, current evidence does not establish low bone density as a direct cause of cognitive decline, and the relationship may involve influences in both directions.

First, What Does Bone Density Actually Mean?

Bone mineral density is an estimate of how much mineral, particularly calcium and phosphorus, is packed into a given area of bone and is commonly measured using dual-energy X-ray absorptiometry, or DXA. Lower BMD can indicate reduced bone strength, but density is only one part of the fracture equation. Bone architecture, bone turnover, muscle strength, balance, falls and other medical factors also influence fracture risk. Osteoporosis is a clinical skeletal disease characterized by reduced bone strength and increased fracture risk, so it should not simply be treated as another term for “slightly low bone density.”

This distinction matters when interpreting research on the brain–bone relationship because studies do not all measure the same thing. Some investigate BMD values, while others examine diagnosed osteoporosis, changes in bone density over time or fractures. These measures overlap, but they capture different aspects of skeletal health and should not automatically be treated as interchangeable.

What Have Studies Found?

Several longitudinal studies have identified a relationship between skeletal and cognitive health. One important example comes from the Rotterdam Study, in which 3,651 adults with a median age of approximately 72 years were followed over time. Lower femoral-neck BMD was associated with a greater likelihood of developing dementia, including Alzheimer disease. A later meta-analysis combining data from the Framingham Heart Study, Rotterdam Study and Rush Memory and Aging Project included 4,431 adults and 606 incident dementia cases and similarly found that higher baseline BMD was associated with a lower subsequent risk of dementia, although evidence relating prior bone loss itself to dementia was less consistent.

More recently, a large 2025 population-based cohort of 176,150 community-dwelling adults aged 65 and older in Shenzhen, China, found that physician-diagnosed osteoporosis was associated with a higher risk of subsequent all-cause dementia after adjustment for numerous demographic, lifestyle and medical factors. The association was stronger among participants who had experienced an osteoporotic fracture. These findings strengthen the case for studying the connection, but they remain observational evidence and therefore cannot establish that osteoporosis or low BMD directly causes dementia.

Why Might Bones and the Brain Be Connected?

One explanation is that both systems are exposed to many of the same pressures of aging. Physical inactivity, inadequate nutrition, hormonal changes, chronic inflammation, metabolic disorders and vascular disease can influence skeletal and brain health simultaneously. Someone who becomes less active, for example, may lose bone and muscle strength while also experiencing fewer opportunities for cardiovascular and cognitive stimulation.

Researchers are also investigating a more direct possibility: bone may actively communicate with the brain. Bone is increasingly recognized as an endocrine organ capable of releasing signalling molecules known as osteokines. These substances can enter circulation and influence tissues beyond the skeleton. A 2025 Bone Research review describes several possible bone–brain pathways involving molecules such as osteocalcin, sclerostin and lipocalin-2, along with neural, hormonal and inflammatory signals originating elsewhere in the body.

Osteocalcin: A Bone Hormone With a Brain Story

One of the most extensively studied bone-derived signals is osteocalcin, a protein produced by bone-forming cells. Experimental research suggests that osteocalcin can reach the brain and influence processes involved in learning, memory, stress responses and neuronal function. These findings have helped reshape the traditional view of bone as purely structural tissue and raised the possibility that skeletal activity may contribute to whole-body regulation.

The important caveat is that much of the mechanistic evidence comes from animal and experimental research. Demonstrating that osteocalcin can influence neurons in a laboratory or animal model does not establish that naturally occurring changes in human osteocalcin produce clinically meaningful changes in cognition. Osteocalcin is therefore an intriguing component of the bone–brain story, but it is not currently a cognitive treatment or established dementia biomarker.

Sclerostin: Another Potential Messenger

Sclerostin, a protein produced primarily by osteocytes, is another molecule attracting attention. It normally inhibits the Wnt/β-catenin pathway, which is an important regulator of bone formation. Researchers are now examining whether changes in this signalling pathway could also influence brain biology.

Recent reviews describe experimental evidence suggesting that sclerostin and Wnt signaling may interact with pathways involved in neuronal function and neurodegeneration, while some human research has linked circulating sclerostin with markers associated with Alzheimer pathology. These findings provide an interesting mechanistic direction, but the evidence remains preliminary. Low bone density should not currently be interpreted as evidence that abnormal sclerostin signaling is driving an individual’s cognitive decline.

The Inflammation and Vascular Connection

Inflammation provides another possible bridge between the skeleton and the brain. Persistent systemic inflammation can influence bone remodeling while also affecting the brain’s immune environment. Microglia, the resident immune cells of the central nervous system, respond to inflammatory signals and can influence neuronal and synaptic function, while inflammatory pathways can simultaneously alter the balance between bone formation and bone resorption.

The vascular system may provide another shared route. Vascular dysfunction can reduce cerebral blood flow and compromise the blood–brain barrier, contributing to cognitive decline during aging. The same cardiovascular and metabolic conditions that increase vascular risk may also influence skeletal health. This creates an important challenge for researchers: determining how much of the observed bone–brain relationship reflects a genuine biological signal from bone and how much reflects the many health conditions that affect both organs.

Could Cognitive Decline Also Affect Bone Health?

The relationship may work in the opposite direction as well. Cognitive impairment can make it increasingly difficult for someone to remain physically active, eat adequately, manage medications correctly or maintain chronic disease care. Changes in balance, judgment and mobility can also increase fall risk, while prolonged inactivity can contribute to bone and muscle loss.

This means that declining cognition could contribute indirectly to poorer skeletal health, creating a feedback loop in which reduced activity, nutritional challenges, falls and loss of independence affect both systems. The evidence therefore increasingly supports thinking about the relationship as potentially bidirectional rather than a simple bone-to-brain pathway.

The Role of Falls, Fractures and Physical Activity

The connection becomes particularly visible when falls and fractures enter the picture. A hip or vertebral fracture can substantially reduce mobility and independence, while pain, hospitalization and disruption of normal routines can create additional physical and psychological stress. Reduced movement after a fracture may accelerate muscle loss and reduce social participation, both of which can have consequences for overall cognitive well-being.

A 2026 systematic review and meta-analysis also found an association between falls and subsequent dementia risk among middle-aged and older adults. This does not demonstrate that falling causes dementia; rather, falls may sometimes signal underlying neurological, physical or health changes that are already developing. Bone health therefore fits naturally into a broader healthy-aging framework that includes muscle strength, balance, mobility, cardiovascular health and cognitive engagement.

Is Low Bone Density a Warning Sign for Cognitive Decline?

Low bone density by itself should not be interpreted as evidence that someone is developing dementia. BMD is influenced by age, genetics, hormonal status, nutrition, physical activity, medications and numerous medical conditions, and a single DXA result cannot capture the complexity of brain aging.

What the emerging research suggests is more nuanced: bone health may provide one additional window into overall aging biology. When low bone density occurs alongside frailty, muscle loss, reduced mobility, vascular disease or nutritional problems, the combination may point toward a broader need to evaluate health and functional status. It is the pattern of interconnected risks; not the bone-density number alone, that is clinically more informative.

Could Protecting Bone Also Protect the Brain?

This remains one of the most important unanswered questions. Established bone-health strategies such as appropriate weight-bearing and resistance exercise, adequate nutrition, smoking avoidance, fall prevention and clinical assessment of osteoporosis risk have clear reasons to matter for skeletal health. Many of these same behaviours also support cardiovascular fitness, mobility and broader brain health.

However, it would be premature to claim that treating osteoporosis prevents dementia. The 2025 Shenzhen cohort, for example, found that the association between osteoporosis and dementia appeared weaker among people receiving osteoporosis medications than among those not receiving medication. This is an intriguing observation, but it was not a randomized trial, so people who received treatment may have differed from untreated participants in important ways. Clinical trials specifically designed to determine whether osteoporosis treatment changes cognitive outcomes would provide much stronger evidence.

The Bigger Picture: Think “Bone–Muscle–Brain,” Not Bone Alone

An increasingly useful way to understand this research is to view bone, muscle and brain health as parts of an interconnected system. Healthy bones support mobility, strong muscles help reduce fall risk and maintain independence, and regular physical activity benefits cardiovascular and cognitive health. Adequate nutrition supplies the building blocks needed by bone and muscle while also supporting normal brain function, and staying physically and socially engaged creates opportunities for continued cognitive stimulation.

This perspective does not require claiming that one organ directly controls another. Instead, it recognizes that healthy aging is multidimensional. Research on bone–muscle communication similarly suggests that endocrine, inflammatory, nutritional and mechanical signals can influence both tissues and their interaction over the course of aging.

Recent Research Highlights

Recent evidence has strengthened interest in the relationship between skeletal and cognitive health. A 2025 meta-analysis reported evidence of a potentially bidirectional association between cognitive impairment and reduced bone density, while a large 2025 Chinese cohort linked diagnosed osteoporosis with a greater risk of subsequent dementia. These studies do not establish causation, but together they provide a stronger rationale for investigating the relationship longitudinally.

At the biological level, research is moving beyond the idea that bone is simply a structural tissue. Scientists are investigating bone-derived molecules such as osteocalcin and sclerostin, along with Wnt/β-catenin signaling, inflammatory pathways and vascular mechanisms that could help explain how skeletal and brain health interact. The emerging field therefore points toward a complex communication network rather than a simple pathway in which weaker bones directly produce cognitive decline.

Recent Clinical Studies & Surveys

Human clinical evidence remains predominantly observational, with substantial variation in study populations, methods of measuring bone health and definitions of cognitive outcomes. The large Shenzhen cohort is particularly informative because it included more than 176,000 adults who were initially free of cognitive impairment and adjusted for a broad range of potential confounding factors. Nevertheless, the median follow-up was approximately 2.2 years, and observational research cannot completely eliminate residual confounding or reverse causation.

Future research will benefit from longer follow-up periods, repeated measurements of both bone density and cognition, greater population diversity and, where feasible, randomized evidence examining whether interventions that improve skeletal health also influence cognitive trajectories.

Real-World Perspective: When the Bones Tell a Brain Story

A striking example comes from a 2026 study of adults participating in the Multi-Ethnic Study of Atherosclerosis (MESA). Researchers examined CT-derived spinal bone mineral density alongside brain MRI scans and cognitive testing. Among the participants analysed, lower vertebral bone mineral density was associated with faster decline in global cognition and with changes in brain white matter, including greater accumulation of white-matter hyperintensities and reductions in white-matter integrity. The findings do not prove that low bone density causes cognitive decline, but they add to growing evidence that skeletal and brain health may be connected through shared vascular, inflammatory, metabolic and aging-related pathways. In other words, the health of the skeleton may offer another window into the broader biology of healthy brain aging.

The above example doesn’t mean that the bone loss caused the cognitive change. Instead, it illustrates why researchers are increasingly studying healthy aging as an interconnected biological system rather than a collection of completely independent organs.

Future of Bone–Brain Research

The next generation of studies needs to move beyond asking whether low bone density and cognitive decline occur together and determine what biological processes connect them. Researchers are investigating whether bone-derived hormones influence synaptic function, whether chronic inflammation accelerates changes in both tissues, how Wnt signaling may connect skeletal remodelling with neurodegeneration, and whether vascular or metabolic dysfunction acts as a common bridge.

Another important question is whether improving mobility, muscle strength and skeletal health can influence cognitive trajectories. If future trials demonstrate such effects, bone-health interventions could become part of a more integrated healthy-aging strategy. For now, however, these possibilities remain under investigation rather than established clinical conclusions.

Key Takeaways

• Lower bone density and cognitive decline have been associated in several observational studies.
• The relationship may be bidirectional, with changes in cognition potentially affecting skeletal health as well.
• Aging, inactivity, inflammation, hormonal changes, nutrition and vascular health may contribute to both conditions.
• Bone is also an endocrine organ capable of releasing signaling molecules that may influence other tissues.
• Osteocalcin and sclerostin are among the molecules being investigated in the emerging bone–brain field.
• Wnt/β-catenin signaling is one potential molecular connection.
• Osteoporosis has been associated with higher dementia risk in large cohort studies, but association does not establish causation.
• Osteoporosis treatment has established benefits for skeletal health, but it has not been proven to prevent dementia.
• Bone, muscle, mobility and brain health are interconnected aspects of healthy aging.
• Supporting both skeletal and cognitive health is therefore relevant well before major impairment develops.

FAQ (Frequently Asked Questions)

1. Can low bone density cause cognitive decline?
   Current evidence does not establish that low bone density directly causes cognitive decline. Several studies show an association, but shared risk factors and reverse causation may explain part of the relationship.

2. Is osteoporosis linked to dementia?
   Several observational studies have reported an association between osteoporosis and subsequent dementia risk, including a large 2025 population-based cohort of older adults.

3. What is the bone–brain axis?
   The bone–brain axis describes potential two-way communication between skeletal tissue and the nervous system through hormones, signaling molecules, inflammatory pathways, blood vessels and neural mechanisms.

4. What is osteocalcin?
   Osteocalcin is a protein produced by bone cells. Experimental research suggests that it can influence processes beyond the skeleton, including pathways involved in learning, memory and neuronal function.

5. What is sclerostin?
   Sclerostin is primarily produced by osteocytes and helps regulate bone formation through Wnt signaling. Researchers are investigating whether this pathway also has implications for brain aging.

6. Can dementia affect bone health?
   Yes, potentially. Cognitive impairment can contribute indirectly to poorer bone health through reduced activity, nutritional difficulties, falls, medication-management problems and loss of independence.

7. Can exercise support both bones and the brain?
   Regular physical activity, including appropriately prescribed weight-bearing and resistance exercise, supports skeletal and muscle health and is also associated with broader brain-health benefits. Exercise should be adapted to individual health and physical ability.

8. Can osteoporosis medication prevent dementia?
   There is currently insufficient evidence to recommend osteoporosis medication specifically for dementia prevention. Some observational findings are interesting, but they cannot establish a protective causal effect.

9. Should everyone with low BMD have cognitive testing?
   Not necessarily. Low BMD alone does not automatically indicate cognitive impairment or require cognitive testing. Assessment may be appropriate when there are memory or thinking concerns or other clinical reasons.

10. Does low bone density mean the brain is aging faster?
    No. Bone density is influenced by many factors and cannot be used as a stand-alone measure of brain aging.

11. Why are researchers studying bone-derived hormones?
    Bone-derived molecules may provide clues about how skeletal and neural systems communicate. Understanding these pathways could eventually identify biomarkers or therapeutic targets, although most of the work remains experimental.

12. What is the main lesson from the bone–brain connection?
    Healthy aging is interconnected. Supporting mobility, muscle, bone, cardiovascular health and cognitive function may be more meaningful than treating each system as completely separate.

DISCLAIMER: The content of this article is intended solely for general informational purposes and is not a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your doctor or another qualified healthcare professional regarding any medical concerns.